This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: N04.4 (congenital nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis) | Special Copayment Reduction: V263 (rare disease) |
| B. Synonyms | Congenital nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis |
| C. Adult onset | Likelihood of first onset in adulthood very low — the congenital classification presupposes onset within the first year of life, and infectious causes produce symptoms from the neonatal period. Even when associated with complement abnormalities, onset within infancy is typical. |
| 1. History | Histologic classification of endocapillary proliferative glomerulonephritis established in the 1970s; congenital onset shows a pattern similar to postinfectious glomerulonephritis but with different causes |
| 2. Causes | Immune complex deposition associated with congenital infection (streptococcus, syphilis, CMV, etc.); rarely complement pathway gene variants; idiopathic |
| 3. Genetics | Mostly no single-gene cause; possible variants in C3 glomerulopathy-associated complement genes (CFH, CFI, C3, CFHR1-5); AR or sporadic |
| 4. General epidemiology | Congenital endocapillary proliferative nephrotic syndrome is extremely rare; an infantile counterpart of adult poststreptococcal glomerulonephritis is rarely reported |
| 5. Pathophysiology | Subendothelial deposition of immune complexes (antigen-antibody) in the GBM → complement activation → proliferation of endothelial and mesangial cells → intracapillary cell proliferation |
| 6. Symptoms | Acute nephrotic syndrome symptoms (hematuria, proteinuria, hypertension, edema, oliguria); systemic symptoms when preceded by infection |
| 7. Signs | Subendothelial deposits + intracapillary cell proliferation; subendothelial granular IgG and C3 deposits on immunofluorescence; subendothelial electron-dense deposits on electron microscopy |
| 8. Screening | Maternal infection screening; neonatal urine and serum infection tests; complement level measurement |
| 9. Diagnosis | Biopsy, complement panel (C3, C4, CH50, anti-complement factor antibodies), infection tests |
| 10. Treatment | Treatment of the causative infection; steroids/immunosuppressants; consideration of a complement inhibitor (eculizumab); supportive care |
| 11. Prognosis | Spontaneous improvement possible when the infectious cause is removed; risk of recurrence and chronicity with complement gene variants |
| 12. Prevention | Prevention of maternal infection; genetic counseling for families with complement gene variants |
| 13. References | 10 key references (with PMID or DOI) |
Diffuse endocapillary proliferative glomerulonephritis is a histologic type that shows, on light microscopy, a pattern of diffuse proliferation of cells (endothelial cells, mesangial cells, infiltrating monocytes and polymorphonuclear leukocytes) within the glomerular capillary lumina, narrowing the capillary lumina. This histologic type was established as an independent category in the WHO classification of glomerular diseases in the 1970s and is known as the representative histologic type of post-streptococcal glomerulonephritis (PSGN) in adults and children.
Acute PSGN in adults and children is a clinical syndrome characterized by hematuria, proteinuria, edema, and hypertension appearing 1–3 weeks after β-hemolytic streptococcal infection (tonsillitis, pyoderma), and most cases follow a self-limited course. Endocapillary proliferative nephrotic syndrome with congenital or infantile onset has histologic findings similar to PSGN but is fundamentally distinct in age of onset and cause. Neonatal streptococcal infection is possible but rare, and in this age group the causes of endocapillary proliferative congenital nephrotic syndrome are mainly other congenital infections, complement pathway abnormalities, or idiopathic.
Since the 2000s, as the molecular mechanisms of glomerulonephritis related to complement pathway abnormalities (C3 glomerulopathy, redefinition of the membranoproliferative glomerulonephritis classification) have been elucidated, some cases previously classified as 'idiopathic endocapillary proliferative' have been reclassified as being due to variants in complement regulatory genes (CFH, CFI, C3, CFHR1-5, etc.). This highlighted the importance of genetic testing even in cases of congenital onset.
The causes of congenital nephrotic syndrome with endocapillary proliferative glomerulonephritis are broadly divided into infectious and noninfectious (complement pathway abnormalities, idiopathic).
Infectious causes: group A β-hemolytic streptococcus (GAS), the cause of PSGN in adults and children, is possible but rare in the neonatal period. Congenital syphilis, CMV, and other TORCH infections can cause an endocapillary proliferative pattern through an immune complex-mediated mechanism. Staphylococcus aureus-associated glomerulonephritis has also rarely been reported in neonatal sepsis. In these cases, renal findings may improve with treatment of the causative infection.
Complement pathway abnormalities: in the C3 glomerulopathy and membranoproliferative glomerulonephritis (MPGN) classification system, dysregulation of the alternative pathway can cause an endocapillary proliferative pattern. Variants in the CFH (complement factor H), CFI (complement factor I), C3, and CFHR1–5 genes, or anti-CFH autoantibodies, cause persistent activation of the alternative complement pathway, resulting in glomerular injury. These complement pathway abnormalities occur through AR inheritance (CFH, CFI, C3) or sporadically, and infantile onset has also been reported.
Idiopathic: classified as idiopathic when infectious causes and complement abnormalities have been excluded. In this case, circulating immune complexes or unidentified antigen-antibody reactions may be the cause.
Congenital endocapillary proliferative nephrotic syndrome mostly has no single-gene cause, but gene variants associated with complement pathway abnormalities are identified in some cases.
Complement regulatory genes: CFH (complement factor H, 1q32.2): AR variants cause low serum C3 and endocapillary proliferative nephritis. CFI (complement factor I, 4q25): similar mechanism with AR variants. C3 (19p13.3): gain-of-function variants cause C3 glomerulopathy. CFHR1, CFHR3, CFHR5: deletions or variants are associated with C3 glomerulopathy. All of these gene variants are rare, and cases of congenital onset are even rarer.
Mode of inheritance: CFH and CFI variants are autosomal recessive or dominant (incomplete penetrance), and C3 gain-of-function variants are autosomal dominant. Anti-CFH autoantibodies are associated with CFHR1 deletion; they are an acquired cause but have a genetic background. Genetic testing strategy: when complement C3 is low, C4 is normal, and anti-CFH antibodies are negative, a complement gene panel (CFH, CFI, C3, CFHR1-5, MCP/CD46) is performed. The diagnosis is directly reflected in treatment (use of complement inhibitors such as eculizumab).
Congenital endocapillary proliferative nephrotic syndrome is an extremely rare subtype among all congenital nephrotic syndromes, and there are no accurate incidence data. Pediatric post-streptococcal glomerulonephritis (PSGN) remains an important glomerular disease in developing countries, but congenital onset is rare.
The incidence of complement abnormality-associated glomerulonephritis (C3 glomerulopathy, MPGN) is estimated at about 1–2 per million in the overall population, and infantile or congenital onset among these is much rarer. Atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy due to CFH variants are known to have infantile onset, but presentation with an endocapillary proliferative pattern is rare. Worldwide, epidemiological data on congenital endocapillary proliferative nephrotic syndrome are at the level of case reports, and large cohort data are lacking. In Korea, it is registered and managed under Special Copayment Reduction code V263, and cases classified under ICD-10 N04.4 are few.
The pathophysiology of endocapillary proliferative glomerulonephritis can be summarized as immune complex-mediated complement activation and cell proliferation in the glomerular capillary lumen.
Immune complex deposition mechanism: circulating immune complexes (antigen-antibody) or antibodies bound to intraglomerular antigens are deposited subendothelially in the GBM. The deposited immune complexes activate complement via the classical pathway through C1q, C4, and C2 or via the alternative pathway through C3b. Complement activation products (C3a, C5a) are potent chemoattractants that recruit neutrophils and monocytes to the glomerulus, and the C5b-9 membrane attack complex (MAC) directly damages endothelial and mesangial cells. The proliferative response of the injured endothelial and mesangial cells results in narrowing of the capillary lumen and reduced glomerular filtration rate.
Mechanism of alternative complement pathway hyperactivation: with deficiency of complement regulatory proteins such as CFH and CFI, C3 convertase (C3bBb) is persistently activated and C3b fragments are continuously deposited in the glomeruli. This causes complement-mediated glomerular injury even without immune complexes, and in C3 glomerulopathy, isolated C3 deposition on immunofluorescence is characteristic. The mechanism is persistent C3 deposition → activation and proliferation of endothelial and mesangial cells → formation of an endocapillary proliferative pattern.
The main symptoms of congenital endocapillary proliferative nephrotic syndrome are nephrotic syndrome with hematuria or a mixed acute nephritic-nephrotic pattern.
Renal symptoms: simultaneous presentation of microscopic or gross hematuria together with massive (nephrotic-range) proteinuria is the main distinguishing point from other congenital nephrotic syndrome subtypes. Hypoalbuminemia and generalized edema appear as nephrotic components, and hematuria and reduced glomerular filtration rate (elevated serum creatinine, BUN) appear as acute nephritic components. Oliguria or acute kidney injury may occur, and elevated blood pressure is common.
Systemic symptoms with infectious causes: fever, sore throat, impetigo, jaundice (CMV, syphilis), hepatosplenomegaly, and the like may appear due to preceding or concurrent infection. The pattern of renal symptoms appearing 1–3 weeks after streptococcal infection is typical of PSGN, but the latent period in newborns may differ. In cases related to complement abnormalities, rash and findings of thrombotic microangiopathy (TMA) (thrombocytopenia, microangiopathic hemolysis) may accompany it (overlap with aHUS).
Physical examination: generalized edema, elevated blood pressure, oliguria. With infectious causes, fever and signs of throat or skin infection. With aHUS overlap, pallor (anemia), jaundice (hemolysis), and petechiae (thrombocytopenia) are observed.
Laboratory findings: urine: proteinuria (2–4+), hematuria (3+ or RBC casts), red blood cell casts (marker of glomerular bleeding). Serum: low albumin, hyperlipidemia. Elevated BUN and creatinine. Complement: low C3 (complement consumption or dysregulation), C4 low (classical pathway activation) or normal (when only the alternative pathway is activated). ASO (antistreptococcal antibody): differentiation of PSGN. Anti-CFH antibody: evaluation of complement abnormalities. CBC: thrombocytopenia, microangiopathic hemolytic anemia (with aHUS overlap).
Kidney biopsy findings: light microscopy: occlusion or narrowing of the capillary lumen due to diffuse proliferation of endothelial cells, mesangial cells, neutrophils, and monocytes within the glomerular capillary lumen. Subendothelial exudate. Immunofluorescence: subendothelial granular (starry sky pattern) deposits of IgG and C3. Electron microscopy: subendothelial and mesangial electron-dense deposits, endothelial cell swelling and detachment.
General population screening is unnecessary. A systematic approach is needed in cases of clinical suspicion and high-risk situations.
Maternal infection screening: standard prenatal testing is performed in all pregnant women (syphilis VDRL/RPR, hepatitis B, CMV risk assessment; rectovaginal streptococcal culture is limited to group B). When neonatal streptococcal sepsis is confirmed, monitoring for possible renal involvement is performed.
Monitoring of complement levels: in nephrotic syndrome with hematuria + proteinuria + hypertension presenting within a few weeks to 3 months after birth, complement levels (C3, C4, CH50) are measured immediately. With isolated low C3, additional tests to evaluate alternative complement pathway abnormalities (CFH, CFI, C3, anti-CFH antibody, ADAMTS13) are performed. The possibility of atypical hemolytic uremic syndrome (aHUS) is excluded.
The diagnosis of congenital endocapillary proliferative nephrotic syndrome is made by integrating clinical findings, complement tests, kidney biopsy, and tests for the cause.
Clinical and laboratory criteria: the combination of nephrotic syndrome presenting between 3 months and 1 year after birth + hematuria + complement abnormalities (low C3) + a possible preceding infection strongly suggests endocapillary proliferative nephrotic syndrome. Accompanying hematuria, rather than proteinuria alone, is the clinical point of distinction from minimal change disease and FSGS.
Tests for the cause: ASO, anti-DNase B (after streptococcal infection), TORCH IgM panel, serum syphilis tests, HBsAg. Complement panel: C3, C4, CH50, AH50 (alternative pathway), serum CFH and CFI levels, anti-CFH antibody. Blood smear (evaluation of microangiopathic hemolysis), ADAMTS13 activity (to exclude thrombotic thrombocytopenic purpura).
Kidney biopsy: performed when the clinical diagnosis is unclear or there is no response to conservative treatment. Light, immunofluorescence, and electron microscopy confirm the endocapillary proliferative pattern. With isolated C3 deposition on immunofluorescence, C3 glomerulopathy classification (DDD or C3GN) is considered.
Genetic testing: when a complement abnormality is suspected, a gene panel for CFH, CFI, C3, MCP/CD46, THBD, and CFHR1–5 or WES is performed.
Treatment of congenital endocapillary proliferative nephrotic syndrome centers on removal of causative factors and correction of complement abnormalities.
Treatment of infectious causes: penicillin or amoxicillin when streptococcal infection is confirmed. Crystalline penicillin G for congenital syphilis. Intravenous ganciclovir for CMV. After treatment of the causative infection, monitoring of renal findings (normalization of complement, resolution of proteinuria and hematuria).
Complement inhibition therapy: when CFH deficiency or hyperactivation of the alternative complement pathway is confirmed, eculizumab (a C5 inhibitor, including ravulizumab) is considered a treatment option in aHUS and C3 glomerulopathy. When using eculizumab, meningococcal vaccination and prophylactic antibiotics are mandatory. CFH deficiency can be temporarily supplemented with fresh frozen plasma (FFP) or plasma exchange.
Immunosuppressants: steroids (prednisolone) may be used adjunctively in acute endocapillary proliferative nephrotic syndrome, but evidence of efficacy is limited. Cyclophosphamide, MMF, and the like are used for steroid resistance or C3 glomerulopathy. ACE inhibitors/ARBs suppress proteinuria and preserve renal function.
The prognosis of congenital endocapillary proliferative nephrotic syndrome varies greatly depending on the cause.
Infectious causes: after appropriate treatment of the causative infection, renal findings often improve within a few months along with normalization of complement, reaching complete remission. In particular, post-streptococcal glomerulonephritis follows a self-limited course in both adults and children, with complete recovery in about 95%. The course in newborns and infants may also improve after treatment of the cause, but in some, proteinuria or reduced renal function persists.
Complement pathway abnormalities: when overlapping with atypical hemolytic uremic syndrome (aHUS), the risk of progression to acute renal failure and end-stage renal disease is high without eculizumab treatment. C3 glomerulopathy tends to follow a chronic progressive course, reaching ESRD within 10–15 years in about 30–50%. The efficacy of eculizumab is established in aHUS, but its efficacy in C3 glomerulopathy is limited.
Long-term follow-up: normalization of complement levels, proteinuria, blood pressure, and renal function are followed regularly. The possibility of relapse (especially in carriers of complement regulatory gene variants) and signs of progression to ESRD are monitored.
Prevention of congenital endocapillary proliferative nephrotic syndrome consists mainly of prevention of causative infections and genetic counseling for families with complement abnormalities.
Infection prevention: prevention of prenatal syphilis, hepatitis B, and CMV infection (vaccines, personal hygiene). Maternal GBS (group B streptococcus) screening and intrapartum antibiotic prophylaxis to prevent neonatal infection. Early recognition and treatment of neonatal streptococcal sepsis.
Counseling for families with complement gene variants: prenatal genetic diagnosis and genetic counseling are offered to families with confirmed CFH, CFI, C3, or CFHR gene variants. Newborns carrying variants require early complement level monitoring and preparation for immediate eculizumab treatment if aHUS/C3 glomerulopathy develops. Meningococcal vaccination is completed in advance and preparations are made for eculizumab use.